Rice Technologies for Cervical Cancer Screening and Diagnosis
Assessment of New Technologies for the Screening and Diagnosis of Cervical Cancer in Mozambique, A Study to be Conducted in Maputo Central Hospital, Mavalane and Jose Macamo General Hospitals and Mavalane Health Center
M.D. Anderson Cancer Center
678 participants
Mar 24, 2021
INTERVENTIONAL
Conditions
Summary
The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.
Eligibility
Inclusion Criteria5
- year old women
- Women with a positive cervical cancer screening test (abnormal cytology, positive VIA and/or positive HPV test)
- Women with intact cervix
- Women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding
- Willing and capable of providing informed consent
Exclusion Criteria3
- Women under 25 or over 49 years old
- Women who have undergone a total hysterectomy (with removal of the cervix)
- Women who are pregnant or breastfeeding
Interventions
Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05372484